MedTrace Logo

Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy

NCT01693185 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-06-18

Study results available
· View outcomes & findings →

Summary

The aim of the present study is to compare patient's recovery times after elective colonoscopy employing remifentanil only vs conventional combination of midazolam and meperidine

Conditions

  • Diagnostic Colonoscopy Screening

Interventions

DRUG

Remifentanil

continuous infusion 0.4 mcg/kg/min

DRUG

Midazolam

bolus injection

DRUG

Meperidine

bolus injection for 30 sec 1.0 mg/kg

DRUG

placebo (for remifentanil)

normal saline mimic diluted remifentanil

DRUG

placebo (for midazolam)

normal saline mimic to midazolam injection

DRUG

placebo (for meperidine)

normal saline mimic meperidine injection

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Konkuk University Medical Center

    lead OTHER

Principal Investigators

  • Tae-Yop Kim, MD, PhD · Konkuk University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-02-28
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01693185 on ClinicalTrials.gov